There are many reasons for the nation's rising prescription drug spending, which increased 6.3% from August 2015 to August 2016. But you wouldn't think one of them would be that the federal government is actively encouraging drug companies to slap higher price tags on old, cheap products.
The CMS approved the least conservative aspects of Arizona's request to tweak Medicaid in ways that would make consumers more financially responsible for their coverage.
Irvine, Calif.-based Agendia has developed a test the company says makes it easier for physicians to determine if chemotherapy is necessary, sparing many patients from the toxic effects of the drugs, which can leave young women sterile.
Data Points for the week of Oct. 3, 2016, covered the following topics: Antibiotic resistance, deaths attributed to antibiotic resistance, the percentage of antibiotic prescriptions that are unnecessary, use of antibiotics for livestock and hospitals with antibiotic stewardship programs.
An analysis of 55 FDA medical officers, who review and approve drugs, found that more than a quarter went on to work for the pharmaceutical industry, bolstering concerns about ethical conflicts and the efficacy and quality of drugs.
Federal regulators have approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases.
Both Democrat Hillary Clinton and Republican Donald Trump have reportedly tapped policy experts with some healthcare experience for their transition teams.
The FDA has granted tentative approval to a highly contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
The generic drug industry, responding to public anger over big price hikes for some generic products, is calling for action on a bipartisan Senate bill it says would increase the number of cheaper generic drugs and reduce U.S. drug spending.
In the three years since the FDA published final regulations on a unique device identifier system, most manufacturers and distributors have successfully started phasing in UDIs for their products. But few healthcare providers are able to take full advantage of the data.
The threat of infection from tainted medical instruments is growing as the devices become more complex and harder to clean.
The government needs to better protect consumers from high prescription medication costs by setting tougher standards for companies seeking drug exclusivity protection for their brand name products, according to a study.